The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Role of tumor microenvironment in cancer progression and therapeutic strategy
Open accessAbstract
Cancer is now considered a tumor microenvironment (TME) disease, although it was originally thought to be a cell and gene expression disorder. Over the past 20 years, significant advances have been made in understanding the complexity of the TME and its impact on responses to various anticancer therapies, including immunotherapies. Cancer immunotherapy can recognize and kill cancer cells by regulating the body's immune system. It has achieved good therapeutic effects in various solid tumors and hematological malignancies. Recently, blocking of programmed death‐1 (PD‐1), programmed death‐1 ligand‐1 (PD‐L1), and programmed death Ligand‐2 (PD‐L2), the construction of antigen chimeric T cells (CAR‐T) and tumor vaccines have become popular immunotherapies Tumorigenesis, progression, and metastasis are closely related to TME. Therefore, we review the characteristics of various cells and molecules in the TME, the interaction between PD‐1 and TME, and promising cancer immunotherapy therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Dendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
PD-1/PD-L1 pathway: current researches in cancer.
Han, Y., Liu, D., & Li, L. (2020) · PubMed · Cited by 1,585
Engineering exosomes for targeted drug delivery
Liang, Y., Duan, L., Lu, J., & Xia, J. (2021) · Theranostics · doi:10.7150/thno.52570 · Cited by 1,547
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Chanmee, T., Ontong, P., Konno, K., & Itano, N. (2014) · Cancers · doi:10.3390/cancers6031670 · Cited by 1,538
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Poggio, M., Hu, T., Pai, C.-C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.016 · Cited by 1,376
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance
Mashouri, L., Yousefi, H., Aref, A. R., Ahadi, A. M., Molaei, F., & Alahari, S. K. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0991-5 · Cited by 1,363
Arneth, B. (2019) · Medicina · doi:10.3390/medicina56010015 · Cited by 1,250
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
The microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
Radiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H., Deng, L., & Fu, Y.-X. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,070
Lost in translation: animal models and clinical trials in cancer treatment.
(2014) · Europe PMC (PubMed Central) · Cited by 1,033
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 970
Mechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Brudno, J. N., & Kochenderfer, J. N. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.002 · Cited by 899
Exosomes in cancer development, metastasis, and immunity
Zhang, L., & Yu, D. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.004 · Cited by 870
Metabolic Interactions in the Tumor Microenvironment
Lyssiotis, C. A., & Kimmelman, A. C. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.003 · Cited by 853
Patra, K. C., Wang, Q., Bhaskar, P. T., Miller, L., Wang, Z., Wheaton, W., Chandel, N., Laakso, M., Muller, W. J., Allen, E. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.014 · Cited by 853
Self-citationMartinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
Intra-tumor heterogeneity from a cancer stem cell perspective
Prasetyanti, P. R., & Medema, J. P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0600-4 · Cited by 800
Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 706
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 677
Radiation-induced cell death mechanisms
Eriksson, D., & Stigbrand, T. (2010) · Tumor Biology · doi:10.1007/s13277-010-0042-8 · Cited by 666
Fiori, M. E., Di Franco, S., Villanova, L., Bianca, P., Stassi, G., & De Maria, R. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0994-2 · Cited by 647
Metabolic modulation of tumours with engineered bacteria for immunotherapy
Canale, F. P., Basso, C., Antonini, G., Perotti, M., Li, N., Sokolovska, A., Neumann, J., James, M. J., Geiger, S., Jin, W., et al. (2021) · Nature · doi:10.1038/s41586-021-04003-2 · Cited by 619
Mast Cell Function: A New Vision of an Old Cell
da Silva, E. Z. M., Jamur, M. C., & Oliver, C. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155414545334 · Cited by 604
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Yearley, J. H., Gibson, C., Yu, N., Moon, C., Murphy, E., Juco, J., Lunceford, J., Cheng, J., Chow, L. Q. M., Seiwert, T. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1761 · Cited by 594
The Intestinal Microbiota and Colorectal Cancer
Cheng, Y., Ling, Z., & Li, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.615056 · Cited by 582
Erdogan, B., & Webb, D. J. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160387 · Cited by 558
Zheng, Y., Wang, T., Tu, X., Huang, Y., Zhang, H., Tan, D., Jiang, W., Cai, S., Zhao, P., Song, R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0650-9 · Cited by 550
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W., Wang, J., Wang, X., & Fu, Y.-X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 472
Self-citationTanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Grada, Z., Hegde, M., Byrd, T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.32 · Cited by 458
Neophytou, C. M., Panagi, M., Stylianopoulos, T., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13092053 · Cited by 456
STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis
Priego, N., Zhu, L., Monteiro, C., Mulders, M., Wasilewski, D., Bindeman, W., Doglio, L., Martínez, L., Martínez-Saez, E., Ramón y Cajal, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0044-4 · Cited by 452
Moon, E. K., Wang, L.-C., Dolfi, D. V., Wilson, C. B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Puré, E., Milone, M. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2627 · Cited by 404
Ohta, A., Kini, R., Ohta, A., Subramanian, M., Madasu, M., & Sitkovsky, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00190 · Cited by 398
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science · doi:10.1126/science.aax0701 · Cited by 396
New development in CAR-T cell therapy
Wang, Z., Wu, Z., Liu, Y., & Han, W. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0423-1 · Cited by 396
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Zak, K. M., Grudnik, P., Magiera, K., Dömling, A., Dubin, G., & Holak, T. A. (2017) · Structure · doi:10.1016/j.str.2017.06.011 · Cited by 388
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
Chan, L.-C., Li, C.-W., Xia, W., Hsu, J.-M., Lee, H.-H., Cha, J.-H., Wang, H.-L., Yang, W.-H., Yen, E.-Y., Chang, W.-C., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126022 · Cited by 382
Tumor microenvironment and cancer therapy resistance
Sun, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.07.044 · Cited by 381
Hegde, M., Corder, A., Chow, K. K., Mukherjee, M., Ashoori, A., Kew, Y., Zhang, Y. J., Baskin, D. S., Merchant, F. A., Brawley, V. S., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.185 · Cited by 373
Self-citationImplications of the tumor immune microenvironment for staging and therapeutics
Taube, J. M., Galon, J., Sholl, L. M., Rodig, S. J., Cottrell, T. R., Giraldo, N. A., Baras, A. S., Patel, S. S., Anders, R. A., Rimm, D. L., et al. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.156 · Cited by 358
Pedersen, P. L., Mathupala, S., Rempel, A., Geschwind, J. F., & Ko, Y. H. (2002) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(02)00248-7 · Cited by 356
The role of exosomal PD-L1 in tumor progression and immunotherapy
Xie, F., Xu, M., Lu, J., Mao, L., & Wang, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1074-3 · Cited by 348
Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy
Barrett, R. L., & Puré, E. (2020) · eLife · doi:10.7554/elife.57243 · Cited by 346
Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment
Chen, B., Dai, W., He, B., Zhang, H., Wang, X., Wang, Y., & Zhang, Q. (2017) · Theranostics · doi:10.7150/thno.16684 · Cited by 342
PKM2 and cancer: The function of PKM2 beyond glycolysis
DONG, G., MAO, Q., XIA, W., XU, Y., WANG, J., XU, L., & JIANG, F. (2016) · Oncology Letters · doi:10.3892/ol.2016.4168 · Cited by 325
Lee, S.-H., Cho, S.-Y., Yoon, Y., Park, C., Sohn, J., Jeong, J.-J., Jeon, B.-N., Jang, M., An, C., Lee, S., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-020-00831-6 · Cited by 325
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Cekic, C., Day, Y.-J., Sag, D., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3583 · Cited by 304
Gong, X., Li, X., Jiang, T., Xie, H., Zhu, Z., Zhou, F., & Zhou, C. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.014 · Cited by 303
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
Lopez-Beltran, A., Cimadamore, A., Blanca, A., Massari, F., Vau, N., Scarpelli, M., Cheng, L., & Montironi, R. (2021) · Cancers · doi:10.3390/cancers13010131 · Cited by 279
Ectonucleotidases as Regulators of Purinergic Signaling in Thrombosis, Inflammation, and Immunity
Deaglio, S., & Robson, S. C. (2011) · Advances in Pharmacology · doi:10.1016/b978-0-12-385526-8.00010-2 · Cited by 250
Natural and Induced T Regulatory Cells in Cancer
Adeegbe, D. O., & Nishikawa, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00190 · Cited by 248
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
Gong, B., Kiyotani, K., Sakata, S., Nagano, S., Kumehara, S., Baba, S., Besse, B., Yanagitani, N., Friboulet, L., Nishio, M., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180870 · Cited by 242
The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications
Spiotto, M., Fu, Y.-X., & Weichselbaum, R. R. (2016) · Science Immunology · doi:10.1126/sciimmunol.aag1266 · Cited by 239
Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
Inman, B. A., Longo, T. A., Ramalingam, S., & Harrison, M. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1417 · Cited by 238
CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells
Legut, M., Dolton, G., Mian, A. A., Ottmann, O. G., & Sewell, A. K. (2018) · Blood · doi:10.1182/blood-2017-05-787598 · Cited by 228
Microenvironmental Regulation of Tumor Progression and Therapeutic Response in Brain Metastasis
Schulz, M., Salamero-Boix, A., Niesel, K., Alekseeva, T., & Sevenich, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01713 · Cited by 221
Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy
Gupta, S., Roy, A., & Dwarakanath, B. S. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00068 · Cited by 218
Gong, A.-Y., Zhou, R., Hu, G., Li, X., Splinter, P. L., O'Hara, S. P., LaRusso, N. F., Soukup, G. A., Dong, H., & Chen, X.-M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1325 · Cited by 217
Yang, L., Li, A., Lei, Q., & Zhang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0804-8 · Cited by 215
Self-citationCancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy
Igarashi, Y., & Sasada, T. (2020) · Journal of Immunology Research · doi:10.1155/2020/5825401 · Cited by 214
Noman, M. Z., Hasmim, M., Lequeux, A., Xiao, M., Duhem, C., Chouaib, S., Berchem, G., & Janji, B. (2019) · Cells · doi:10.3390/cells8091083 · Cited by 212
Roberti, M. P., Yonekura, S., Duong, C. P. M., Picard, M., Ferrere, G., Tidjani Alou, M., Rauber, C., Iebba, V., Lehmann, C. H. K., Amon, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0882-8 · Cited by 208
Look back in anger – what clinical studies tell us about preclinical work
Hartung, T. (2013) · ALTEX · doi:10.14573/altex.2013.3.275 · Cited by 200
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
Ai, L., Chen, J., Yan, H., He, Q., Luo, P., Xu, Z., & Yang, X. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s267433 · Cited by 199
Metabolic crosstalk in the breast cancer microenvironment
Dias, A. S., Almeida, C. R., Helguero, L. A., & Duarte, I. F. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.002 · Cited by 195
Scarfò, I., & Maus, M. V. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0230-9 · Cited by 194
Fischer, G. M., Vashisht Gopal, Y. N., McQuade, J. L., Peng, W., DeBerardinis, R. J., & Davies, M. A. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12661 · Cited by 193
The Biology Behind mTOR Inhibition in Sarcoma
Wan, X., & Helman, L. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-1007 · Cited by 180
Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression
Heinecke, J. L., Ridnour, L. A., Cheng, R. Y. S., Switzer, C. H., Lizardo, M. M., Khanna, C., Glynn, S. A., Hussain, S. P., Young, H. A., Ambs, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401799111 · Cited by 177
Effects of tumor metabolic microenvironment on regulatory T cells
Wang, Y.-A., Li, X.-L., Mo, Y.-Z., Fan, C.-M., Tang, L., Xiong, F., Guo, C., Xiang, B., Zhou, M., Ma, J., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0913-y · Cited by 176
Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint
Magiera‐Mularz, K., Skalniak, L., Zak, K. M., Musielak, B., Rudzinska‐Szostak, E., Berlicki, Ł., Kocik, J., Grudnik, P., Sala, D., Zarganes‐Tzitzikas, T., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707707 · Cited by 175
Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy
Morrissey, S. M., & Yan, J. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.03.002 · Cited by 172
Immune targets in the tumor microenvironment treated by radiotherapy
Ozpiskin, O. M., Zhang, L., & Li, J. J. (2019) · Theranostics · doi:10.7150/thno.32648 · Cited by 163
Self-citationThe effect of environmental chemicals on the tumor microenvironment
Casey, S. C., Vaccari, M., Al‐Mulla, F., Al-Temaimi, R. A., Amedei, A., Barcellos‐Hoff, M. H., Brown, D. G., Chapellier, M., Christopher, J., Curran, C. S., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv035 · Cited by 162
SnapShot: Cancer-Associated Fibroblasts
Park, D., Sahai, E., & Rullan, A. (2020) · Cell · doi:10.1016/j.cell.2020.03.013 · Cited by 162
Guzik, K., Tomala, M. D., Muszak, D., Konieczny, M., Hec, A., Tyrcha, U., Pustuła, M., Butera, R., Dömling, A. S. S., & Holak, T. A. (2019) · Molecules · doi:10.3390/molecules24112071 · Cited by 160
Buhrmann, C., Kraehe, P., Lueders, C., Shayan, P., Goel, A., & Shakibaei, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107514 · Cited by 154
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
Derer, A., Spiljar, M., Bäumler, M., Hecht, M., Fietkau, R., Frey, B., & Gaipl, U. S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00610 · Cited by 139
Yee, D., Shah, K., Coles, M. C., Sharp, T. V., & Lagos, D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.809053 · Cited by 138
Darragh, L. B., Oweida, A. J., & Karam, S. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03154 · Cited by 134
3D approaches to model the tumor microenvironment of pancreatic cancer
Bort, E. T., Kieler, M., Sharma, S., Candido, J. B., & Loessner, D. (2020) · Theranostics · doi:10.7150/thno.42441 · Cited by 125
The Insulin-Like Growth Factor System in Bone
Kawai, M., & Rosen, C. J. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.013 · Cited by 106
Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
Ren, J., & Zhao, Y. (2017) · Protein & Cell · doi:10.1007/s13238-017-0410-x · Cited by 105
The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals
Philips, E. A., García‐España, A., Tocheva, A. S., Ahearn, I. M., Adam, K. R., Pan, R., Mor, A., & Kong, X. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.011747 · Cited by 101
Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Tanegashima, T., Togashi, Y., Azuma, K., Kawahara, A., Ideguchi, K., Sugiyama, D., Kinoshita, F., Akiba, J., Kashiwagi, E., Takeuchi, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3991 · Cited by 95
Product review: Avelumab, an anti-PD-L1 antibody
Collins, J. M., & Gulley, J. L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1551671 · Cited by 91
Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment
Wang, W., Han, Y., Jo, H. A., Lee, J., & Song, Y. S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00893-3 · Cited by 85
Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma
Ahmed, S., Petersen, E. T., Patel, R., & Migden, M. R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1665026 · Cited by 77
Stadler, M., Walter, S., Walzl, A., Kramer, N., Unger, C., Scherzer, M., Unterleuthner, D., Hengstschläger, M., Krupitza, G., & Dolznig, H. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.007 · Cited by 74
Metabolic kinetic modeling provides insight into complex biological questions, but hurdles remain
Strutz, J., Martin, J. P., Greene, J. L., Broadbelt, L. J., & Tyo, K. E. J. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.02.005 · Cited by 65
Lamhamedi-Cherradi, S.-E., Menegaz, B. A., Ramamoorthy, V., Vishwamitra, D., Wang, Y., Maywald, R. L., Buford, A. S., Fokt, I., Skóra, S., Wang, J., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw182 · Cited by 64
Nivolumab in the Treatment of Microsatellite Instability High Metastatic Colorectal Cancer
Sarshekeh, A. M., Overman, M. J., & Kopetz, S. (2018) · Future Oncology · doi:10.2217/fon-2017-0696 · Cited by 60
A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
Tondini, E., Arakelian, T., Oosterhuis, K., Camps, M. G. M., van Duikeren, S., Han, W. G. H., Arens, R., Zondag, G. C. M., van Bergen, J., & OSSENDORP, F. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1652539 · Cited by 56
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
Ngiow, S. F., & Young, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01633 · Cited by 52
Development of IGF-IR inhibitors in pediatric sarcomas
Kolb, E. A., & Gorlick, R. G. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0043-1 · Cited by 51
Dostarlimab in the Treatment of Recurrent or Primary Advanced Endometrial Cancer
Kasherman, L., Ahrari, S., & Lheureux, S. (2020) · Future Oncology · doi:10.2217/fon-2020-0655 · Cited by 49
Molina, E. R., Chim, L. K., Salazar, M. C., Mehta, S. M., Menegaz, B. A., Lamhamedi-Cherradi, S.-E., Satish, T., Mohiuddin, S., McCall, D. C., Zaske, A. M., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.09.029 · Cited by 48
PD-1 induction through TCR activation is partially regulated by endogenous TGF-β
Rekik, R., Hmida, N. B., Hmid, A. B., Zamali, I., Kammoun, N., & Ahmed, M. B. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.104 · Cited by 45
Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives
Ochoa, C. E., & Joseph, R. W. (2018) · Journal of Kidney Cancer and VHL · doi:10.15586/jkcvhl.2018.102 · Cited by 45
Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma
Molina, E. R., Chim, L. K., Barrios, S., Ludwig, J. A., & Mikos, A. G. (2020) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2019.0302 · Cited by 39
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Liang, Y., Yu, M., Zhou, C., & Zhu, X. (2020) · Diagnostic Pathology · doi:10.1186/s13000-020-00977-1 · Cited by 38
The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury
Sun, Y., Tan, J., Miao, Y., & Zhang, Q. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00742-x · Cited by 38
Gut Microbiota for Esophageal Cancer: Role in Carcinogenesis and Clinical Implications
Zhou, J., Sun, S., Luan, S., Xiao, X., Yang, Y., Mao, C., Chen, L., Zeng, X., Zhang, Y., & Yuan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.717242 · Cited by 36
Self-citationKaumaya, P. T. P., Guo, L., Overholser, J. P., Penichet, M. L., & Bekaii‐Saab, T. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1818437 · Cited by 35
Peng, S., Tan, M., Li, Y.-D., Cheng, M. A., Farmer, E. A., Ferrall, L., Gaillard, S. L., Roden, R. B. S., Hung, C., & Wu, T. ‐. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02754-x · Cited by 35
Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors
Ghahri-Saremi, N., Akbari, B., Soltantoyeh, T., Hadjati, J., Ghassemi, S., & Mirzaei, H. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.738456 · Cited by 35
Kamdje, A. H. N., Etet, P. F. S., Simo, R. T., Vecchio, L., Lukong, K. E., & Krampera, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.545126 · Cited by 33
Sceneay, J., Griessinger, C. M., Hoffmann, S. H. L., Wen, S., Wong, C. S. F., Krumeich, S., Kneilling, M., Pichler, B. J., & Möller, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196040 · Cited by 32
Tan, P. H. S., Chia, S. S., Toh, S. L., Goh, J., & Nathan, S. S. (2013) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.1800 · Cited by 30
Durvalumab in NSCLC: latest evidence and clinical potential
Muñoz-Unceta, N., Burgueño, I., Jiménez, E., & Paz-Ares, L. G. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918804151 · Cited by 30
Kotraiah, V., Phares, T. W., Browne, C. D., Pannucci, J., Mansour, M., Noe, A. R., Tucker, K. D., Christen, J. M., Reed, C., MacKay, A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00264 · Cited by 29
PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer
Kadam, P., & Sharma, S. P. (2020) · Vaccines · doi:10.3390/vaccines8020317 · Cited by 29
Myeloid-Derived Suppressor Cells: Facilitators of Cancer and Obesity-Induced Cancer
Ostrand‐Rosenberg, S. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042120-105240 · Cited by 27
Emerging targets for anticancer vaccination: PD-1
Tobias, J., Steinberger, P., Drinić, M., & Wiedermann, U. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100278 · Cited by 25
Hodgkinson, K. M., & Vanderhyden, B. C. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.936382 · Cited by 22
Lee, Y.-H., Yu, C., Yang, Y., Hong, J., & Chiang, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042091 · Cited by 22
Wang, Z., Wang, C., & Chen, G. (2022) · Protein Expression and Purification · doi:10.1016/j.pep.2022.106130 · Cited by 21
Prognostic significance of metabolic enzyme pyruvate kinase M2 in breast cancer
Yang, Y., Wu, K., Liu, Y., Shi, L., Tao, K., & Wang, G. (2017) · Medicine · doi:10.1097/md.0000000000008690 · Cited by 19
Inokuchi, J., & Eto, M. (2019) · Cancer Management and Research · doi:10.2147/cmar.s167708 · Cited by 18
Hope, J. L., Spantidea, P. I., Kiernan, C. H., Stairiker, C. J., Rijsbergen, L. C., van Meurs, M., Brouwers-Haspels, I., Mueller, Y. M., Nelson, D. J., Bradley, L. M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03074 · Cited by 13
Metabolic Interactions Between Tumor and Stromal Cells in the Tumor Microenvironment
Mishra, D., & Banerjee, D. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-83282-7_5 · Cited by 11
Impact of postal correspondence letters on participation in cancer screening: a rapid review
Yakubu, M., Meggetto, O., Lai, Y., Peirson, L., Walker, M. J., & Lofters, A. (2020) · Preventive Medicine · doi:10.1016/j.ypmed.2020.106404 · Cited by 10
Pathomimetic cancer avatars for live-cell imaging of protease activity
Ji, K., Heyza, J. R., Cavallo‐Medved, D., & Sloane, B. F. (2015) · Biochimie · doi:10.1016/j.biochi.2015.09.015 · Cited by 5
Cited by
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
The tumor microenvironment: shaping cancer progression and treatment response
Desai, S. A., Patel, V. P., Bhosle, K. P., Nagare, S. D., & Thombare, K. C. (2025) · Journal of Chemotherapy · doi:10.1080/1120009x.2023.2300224 · Cited by 106
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
(2025) · doi:10.3390/cancers17132102 · Cited by 44
Photothermal and enhanced chemodynamic reinforced anti-tumor therapy based on PDA@POM nanocomposites
Meng, Q., Wang, W., Wang, H., Tao, Y., Anastassova, N., Sun, T., Sun, Y., & Wang, L. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.09.160 · Cited by 25
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
Metadata
- Authors
- Wang, Q., Shao, X., Zhang, Y., Zhu, M., Wang, F. X. C., Mu, J., Li, J., Yao, H., & Chen, K.
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2023-02-21
- Volume
- 12
- Issue
- 10
- Pages
- 11149-11165
- ISSN
- 2045-7634 (ISSN-L)
- OpenAlex
- W4321445485
- Cited by
- 442
- References
- 151
- FWCI
- 45.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.